BR112014021388A2 - composições de microbiota e métodos rela-cionados às mesmas - Google Patents

composições de microbiota e métodos rela-cionados às mesmas

Info

Publication number
BR112014021388A2
BR112014021388A2 BR112014021388A BR112014021388A BR112014021388A2 BR 112014021388 A2 BR112014021388 A2 BR 112014021388A2 BR 112014021388 A BR112014021388 A BR 112014021388A BR 112014021388 A BR112014021388 A BR 112014021388A BR 112014021388 A2 BR112014021388 A2 BR 112014021388A2
Authority
BR
Brazil
Prior art keywords
microbiota
methods
compositions
altering
relative abundance
Prior art date
Application number
BR112014021388A
Other languages
English (en)
Portuguese (pt)
Inventor
P Liou Alice
L Harris Jason
M Kaplan Lee
J Turnbaugh Peter
Original Assignee
Ethicon Endo Surgery Inc
The General Hospital Corp D/B/A Massachusetts General Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49003107&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014021388(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ethicon Endo Surgery Inc, The General Hospital Corp D/B/A Massachusetts General Hospital filed Critical Ethicon Endo Surgery Inc
Publication of BR112014021388A2 publication Critical patent/BR112014021388A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
BR112014021388A 2012-02-29 2013-02-28 composições de microbiota e métodos rela-cionados às mesmas BR112014021388A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261604824P 2012-02-29 2012-02-29
US13/780,284 US9173910B2 (en) 2012-02-29 2013-02-28 Compositions of microbiota and methods related thereto
PCT/US2013/028271 WO2013130773A2 (en) 2012-02-29 2013-02-28 Compositions of microbiota and methods related thereto

Publications (1)

Publication Number Publication Date
BR112014021388A2 true BR112014021388A2 (pt) 2017-07-18

Family

ID=49003107

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014021388A BR112014021388A2 (pt) 2012-02-29 2013-02-28 composições de microbiota e métodos rela-cionados às mesmas

Country Status (6)

Country Link
US (11) US9173910B2 (enExample)
EP (1) EP2836224A4 (enExample)
CN (3) CN110201003A (enExample)
BR (1) BR112014021388A2 (enExample)
IN (1) IN2014DN07752A (enExample)
WO (1) WO2013130773A2 (enExample)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS63299B1 (sr) 2010-02-01 2022-07-29 Rebiotix Inc Bakterioterapija clostridium difficile kolitisa
CN110201003A (zh) 2012-02-29 2019-09-06 伊西康内外科公司 微生物区系的组合物及与其相关的方法
WO2014075745A1 (en) * 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders
US9881135B2 (en) * 2012-12-13 2018-01-30 Metabogen Ab Identification of a person having risk for developing type 2 diabetes
US10633714B2 (en) 2013-07-21 2020-04-28 Pendulum Therapeutics, Inc. Methods and systems for microbiome characterization, monitoring and treatment
US9549703B2 (en) 2013-11-27 2017-01-24 Elwha Llc Devices and methods for sampling and profiling microbiota of skin
US10152529B2 (en) 2013-08-23 2018-12-11 Elwha Llc Systems and methods for generating a treatment map
US9805171B2 (en) 2013-08-23 2017-10-31 Elwha Llc Modifying a cosmetic product based on a microbe profile
US10010704B2 (en) 2013-08-23 2018-07-03 Elwha Llc Systems, methods, and devices for delivering treatment to a skin surface
US9526480B2 (en) 2013-11-27 2016-12-27 Elwha Llc Devices and methods for profiling microbiota of skin
US20150057623A1 (en) * 2013-08-23 2015-02-26 Elwha Llc Systems, Methods, and Devices for Delivering Treatment to a Skin Surface
US9557331B2 (en) 2013-08-23 2017-01-31 Elwha Llc Systems, methods, and devices for assessing microbiota of skin
US9811641B2 (en) 2013-08-23 2017-11-07 Elwha Llc Modifying a cosmetic product based on a microbe profile
US9526450B2 (en) 2013-11-27 2016-12-27 Elwha Llc Devices and methods for profiling microbiota of skin
US9610037B2 (en) 2013-11-27 2017-04-04 Elwha Llc Systems and devices for profiling microbiota of skin
EP3134509A4 (en) 2014-04-23 2017-09-13 Cornell University Modulation of fat storage in a subject by altering population levels of christensenellaceae in the gi tract
PL3138031T3 (pl) 2014-04-28 2023-04-11 Yeda Research And Development Co., Ltd. Sposób i urządzenie do przewidywania odpowiedzi na pokarm
KR101740893B1 (ko) 2014-05-20 2017-06-13 주식회사 엠디헬스케어 Ａｋｋｅｒｍａｎｓｉａ ｍｕｃｉｎｉｐｈｉｌａ 균에서 유래하는 세포밖 소포를 유효성분으로 함유하는 대사질환의 치료 또는 예방용 조성물
WO2015178653A1 (ko) * 2014-05-20 2015-11-26 이화여자대학교 산학협력단 Akkermansia muciniphila 균에서 유래하는 세포밖 소포를 유효성분으로 함유하는 대사질환의 치료 또는 예방용 조성물
WO2016033439A2 (en) * 2014-08-28 2016-03-03 Yale University Compositions and methods for the treating an inflammatory disease or disorder
ES2828952T3 (es) * 2014-10-02 2021-05-28 Inst Nat Sante Rech Med Composiciones alimenticias para inducir la saciedad y prolongar la saciedad en sujetos que lo necesitan
CN113730442A (zh) * 2014-10-31 2021-12-03 潘德勒姆治疗公司 与病症的微生物治疗和诊断有关的方法和组合物
EP3510876A1 (en) * 2015-01-26 2019-07-17 Stephanie Lynch Broth compositions and their use as prebiotics
AU2016257315A1 (en) 2015-05-06 2017-11-23 Université Catholique de Louvain Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status
EP3302703B1 (en) 2015-06-01 2021-08-25 Xeno Biosciences Inc. Compositions for use in modulating the gut microbiota and managing weight
US10828340B2 (en) 2015-06-09 2020-11-10 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
EP3307906B1 (en) * 2015-06-09 2020-10-14 Regents of the University of Minnesota Methods for detecting risk of having a bloodstream infection
DK3626081T3 (da) * 2015-09-10 2022-02-28 Univ Catholique Louvain Pasteuriseret akkermansia til fremme af vægttab
US11066711B2 (en) 2015-12-08 2021-07-20 Mayo Foundation For Medical Education And Research Biomarkers for predicting Clostridium difficile infection treatment outcome
GB2557823A (en) 2016-03-04 2018-06-27 Univ California Microbial consortium and uses thereof
WO2017180987A1 (en) * 2016-04-15 2017-10-19 National Health Research Institutes Anti-obesity microbiota compositions and preparation methods and uses thereof
US10293005B2 (en) 2016-04-19 2019-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of gram negative species to treat atopic dermatitis
MX2018012719A (es) 2016-04-19 2019-05-30 Us Health Ram negativas para tratar la dermatitis atopica.
WO2017218680A1 (en) 2016-06-14 2017-12-21 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection
US9999641B2 (en) 2016-06-14 2018-06-19 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection
US20180030403A1 (en) 2016-07-28 2018-02-01 Bobban Subhadra Devices, systems and methods for the production of humanized gut commensal microbiota
US10441612B2 (en) * 2016-08-16 2019-10-15 Taichung Veterans General Hospital Intestinal microbe therapy, composition therefor and method for preparing the same
US11311573B2 (en) 2016-11-30 2022-04-26 Xeno Biosciences Inc. Pharmaceutical preparations and methods to manage weight and to modulate the gut microbiota
CN107043714B (zh) * 2016-12-13 2021-03-12 广州康泽医疗科技有限公司 一种益生菌及其制备方法
WO2018136884A1 (en) * 2017-01-23 2018-07-26 The Regents Of The University Of California Compositions and methods for treating obesity and inducing weight loss
CN111372596A (zh) 2017-08-30 2020-07-03 潘德勒姆治疗公司 用于治疗微生物组相关病症的方法和组合物
MX2020004204A (es) * 2017-10-13 2020-08-13 Rebiotix Inc Indice de salud del microbioma.
WO2019118984A2 (en) 2017-12-15 2019-06-20 Solarea Bio, Inc. Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome
EP3735134A4 (en) * 2018-01-04 2022-01-19 White Dog Labs, Inc. METHOD AND COMPOSITION FOR IMPROVING ANIMAL HEALTH COMPRISING ORGANIC CELLS CONSISTING OF STEM IN THE ORDER CLOSTRIDIALES
WO2019199895A1 (en) 2018-04-10 2019-10-17 Siolta Therapeutics, Inc. Microbial consortia
SG11202011188SA (en) 2018-05-11 2020-12-30 Forte Subsidiary Inc Compositions for the treatment of skin conditions
AU2019306649A1 (en) 2018-07-19 2021-02-04 Pendulum Therapeutics, Inc. Methods and compositions for microbial engraftment
CN112888447A (zh) 2018-08-17 2021-06-01 韦丹塔生物科学股份有限公司 减少菌群失调和恢复微生物群系的方法
US11980647B2 (en) 2018-09-05 2024-05-14 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
EP3846830A4 (en) 2018-09-05 2022-07-06 Solarea Bio, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MUSCULOSKELETAL DISEASES
WO2020056494A1 (en) * 2018-09-18 2020-03-26 Mcpharma Biotech Inc. Detection, treatment, and monitoring of microbiome-induced metabolic dysfunction
CN110964650B (zh) * 2018-09-27 2022-10-11 上海上药信谊药厂有限公司 一种用于预防和治疗代谢疾病的菌株及其应用
ES2763874B2 (es) * 2018-11-30 2020-10-13 Consejo Superior Investigacion Phascolarctobacterium faecium para su uso en la prevencion y tratamiento de la obesidad y sus comorbilidades
WO2021030091A1 (en) * 2019-08-09 2021-02-18 The Regents Of The University Of California Compositions and methods for treating metabolic disease
US20240226186A9 (en) * 2019-09-25 2024-07-11 Healthbiome Obligate anaerobic human intestinal microbe for cancer treatment, and use thereof
JP7624449B2 (ja) 2019-10-07 2025-01-30 シオルタ・セラピューティクス，インコーポレイテッド 治療用医薬組成物
DK180598B1 (da) * 2020-02-21 2021-10-14 Sander Wilbek Theis Stivelsespropanoat anvendt som tilsætningsstof og/eller kosttilskud til mennesker til forebyggelse af overvægt og fedme
CN111388488A (zh) * 2020-04-10 2020-07-10 中国海洋大学 半乳寡糖及其衍生物在作为防治非酒精性脂肪肝药物中的应用
JP2023534047A (ja) * 2020-07-17 2023-08-07 ディーエスエム・ニュートリショナル・プロダクツ・エルエルシー オリゴ糖組成物及び使用方法
BE1028339B1 (fr) 2020-11-09 2021-12-21 A Mansia Biotech Composition comprenant de l'Akkermansia muciniphila et de l'extrait de thé vert
WO2022155443A1 (en) * 2021-01-15 2022-07-21 Yale University Compositions and methods for treating and preventing diseases or disorders using inter-species interactions
US20240268432A1 (en) 2021-07-23 2024-08-15 Universidade Católica Portuguesa - Ucp Encapsulated bacterial, methods and uses thereof
AU2022391767A1 (en) 2021-11-22 2024-07-04 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
US20230190834A1 (en) 2021-12-21 2023-06-22 Solarea Bio, Inc. Immunomodulatory compositions comprising microbial entities

Family Cites Families (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1423823A (fr) 1964-11-20 1966-01-07 Azote Office Nat Ind Procédé de reformage catalytique et sous pression élevée des hydrocarbures pétroliers par la vapeur
US3625214A (en) 1970-05-18 1971-12-07 Alza Corp Drug-delivery device
US4906474A (en) 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4789734A (en) 1985-08-06 1988-12-06 La Jolla Cancer Research Foundation Vitronectin specific cell receptor derived from mammalian mesenchymal tissue
WO1988001213A1 (en) 1986-08-18 1988-02-25 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
US5143845A (en) 1986-09-03 1992-09-01 Toa Pharmaceutical Co., Ltd. Mixture of saccarifying lactic acid producing and butyric acid producing bacteria
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5811128A (en) 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5443826A (en) 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
DE68928665T2 (de) 1988-08-02 1998-11-12 Gastro Services Pty Ltd Behandlung von gastro-intestinalen krankheiten
JP2961182B2 (ja) 1990-03-09 1999-10-12 ミヤリサン株式会社 クロストリジウム・ディフィシル下痢症および偽膜性大腸炎の予防ならびに治療用医薬組成物
JP2961184B2 (ja) 1990-05-07 1999-10-12 ミヤリサン株式会社 クロストリジウム・ディフィシル下痢症および偽膜性大腸炎の予防ならびに治療用医薬組成物
CA2153391C (en) 1993-01-11 2000-08-15 Kenneth Rock Inducing cytotoxic t lymphocyte responses
GB9306473D0 (en) 1993-03-29 1993-05-19 Bioglan Lab Ltd Pharmaceutically useful compounds
US6241983B1 (en) 1994-10-28 2001-06-05 Metagenics, Inc. Bacteria-and fiber-containing composition for human gastrointestinal health
US5531989A (en) 1994-10-28 1996-07-02 Metagenics, Inc. Immunoglobulin and fiber-containing composition for human gastrointestinal health
EP0935523B1 (en) 1996-10-28 2004-09-29 Inc. General Mills Embedding and encapsulation of controlled release particles
CZ2001951A3 (cs) 1998-09-17 2001-11-14 Baxter Healthcare S. A. Prostředky obsahující streptokokový Cbeta protein
ID30071A (id) 1998-12-11 2001-11-01 Urex Biotech Inc Pemberian oral lactobacillus untuk pengobatan dan pencegahan infeksi urogental
ID29150A (id) 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
US7056661B2 (en) 1999-05-19 2006-06-06 Cornell Research Foundation, Inc. Method for sequencing nucleic acid molecules
US6926891B1 (en) 1999-08-05 2005-08-09 Nestec S.A. Treatment of diarrhea with strains of Bifidobacterium longum
JP4580542B2 (ja) 2000-05-17 2010-11-17 株式會社バイオニア 肥満又は糖尿病治療用微生物及びその微生物を含む医薬組成物
US20020013270A1 (en) 2000-06-05 2002-01-31 Bolte Ellen R. Method for treating a mental disorder
US20040062757A1 (en) 2001-06-05 2004-04-01 Finegold Sydney M. Method of testing gastrointestinal diseases associated with species of genus clostridium
US20040170617A1 (en) 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
FI110668B (fi) 2000-06-20 2003-03-14 Aboatech Ab Oy Probioottien käyttö atooppisten sairauksien primaariseen ehkäisyyn
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
EP1227152A1 (en) 2001-01-30 2002-07-31 Société des Produits Nestlé S.A. Bacterial strain and genome of bifidobacterium
PL367083A1 (en) 2001-02-06 2005-02-21 Societe Des Produits Nestle S.A. Endotoxin binding by lactic acid bacteria and bifidobacteria
WO2002085415A1 (en) 2001-04-17 2002-10-31 Biomatrix, Inc Non-digestible sugar-coated products and process
US7101565B2 (en) 2002-02-05 2006-09-05 Corpak Medsystems, Inc. Probiotic/prebiotic composition and delivery method
US20050069505A1 (en) 2002-02-21 2005-03-31 Lionel Breton Orally administrable composition for the photoprotection of the skin
ITBO20020564A1 (it) 2002-09-06 2004-03-07 Alfa Wassermann Spa Bifidobatteri e preparazioni che li contengono.
SE526711C2 (sv) 2003-01-31 2005-10-25 Probi Ab Nya stammar av Bifidobacterium med förmåga att överleva i magtarmkanalen och producera glutamin in vivo, samt kompositioner och användningar därav
US8617870B2 (en) 2003-03-13 2013-12-31 University Of Ottawa Antioxidant producing bacterium and uses thereof
GB0307026D0 (en) 2003-03-27 2003-04-30 Rowett Res Inst Bacterial supplement
EP1462116A1 (en) 2003-03-29 2004-09-29 Villitech SARL Composition for treating the gastrointestinal tract
US8192733B2 (en) 2003-08-29 2012-06-05 Cobb & Associates Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US20050100559A1 (en) 2003-11-07 2005-05-12 The Procter & Gamble Company Stabilized compositions comprising a probiotic
EP1600060A1 (en) 2004-05-25 2005-11-30 Cognis IP Management GmbH Oral and/or topical compositions comprising prebiotics and fatty acid
WO2006000992A1 (en) 2004-06-23 2006-01-05 L'oreal Method and compositions useful for preventing and/or treating sensitive and/or dry skin
US7862808B2 (en) 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
ITMI20041550A1 (it) 2004-07-29 2004-10-29 Proge Farm Srl Uso di batteri probiotici per la preparazione di composizioni topiche per la protezione dell'epidermide
FR2874825B1 (fr) 2004-09-08 2006-12-08 Genibio Sarl Utilisations d'oligosaccharides prebiotiques benefiques pour la flore vaginale
JP2008518936A (ja) 2004-10-29 2008-06-05 メディミューン，インコーポレーテッド Ｒｓｖ感染症および関連状態を予防および治療する方法
US20060115465A1 (en) 2004-10-29 2006-06-01 Macfarlane George Treatment of gastrointestinal disorders
CN101124318B (zh) 2004-12-28 2013-01-09 明治制果药业株式会社 赋予宿主抗病性的新菌株及细菌细胞组合物
TW200700074A (en) 2005-03-04 2007-01-01 Calpis Co Ltd Inducer of t cell apoptosis
US20070042953A1 (en) 2005-08-16 2007-02-22 Bazan Nicolas G Antiepileptogenic complex of albumin with docosahexaenoate
FR2889958A1 (fr) 2005-08-25 2007-03-02 Lyoct Sa Lab Utilisation d'un symbiotique pour le traitement de la dermatite atopique
EP1776877A1 (en) 2005-10-21 2007-04-25 N.V. Nutricia Method for stimulating the intestinal flora
ITRM20060237A1 (it) 2006-05-03 2007-11-04 Anabasis S R L Uso dei probiotici nella prevenzione e nel trattamento delle congiuntiviti allergiche
EP2040724B1 (en) * 2006-05-18 2011-10-05 Biobalance Llc Biotherapeutic compositions comprising probiotic escherichia coli and metronidazole and uses thereof
CN1850047A (zh) * 2006-06-01 2006-10-25 济南帅华医药科技有限公司 一种含β－内酰胺酶抑制剂和头孢菌素的缓释制剂及其应用
JP5019563B2 (ja) 2006-06-16 2012-09-05 旭化成ケミカルズ株式会社 腸内細菌賦活剤
CN101095698B (zh) 2006-06-26 2010-12-01 青岛东海药业有限公司 酪酸梭菌防治便臭毒素引起的相关症状和疾病的用途
US20080069861A1 (en) 2006-09-19 2008-03-20 National Starch And Chemical Investment Holding Corporation Probiotic/Non-Probiotic Combinations
WO2008076696A2 (en) 2006-12-18 2008-06-26 Washington University In St. Louis The gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder
US9644210B2 (en) 2007-02-22 2017-05-09 Jürgen Schrezenmeir Probiotic gram-positive bacteria for the prophylaxis, suppression, or elimination of allergic reactions in human
WO2008117266A2 (en) 2007-03-28 2008-10-02 Alimentary Health Limited Probiotic bifidobacterium strains
CA2682327A1 (en) 2007-03-28 2008-10-02 Alimentary Health Limited Probiotic bifidobacterium strains
PL2142635T3 (pl) 2007-05-03 2019-01-31 Tobias Olofsson Nowe szczepy bakterii wyizolowane z przewodu wytwarzania miodu u pszczół miodnych
TW200904340A (en) 2007-05-11 2009-02-01 Mannatech Inc Processing of natural polysaccharides by selected non-pathogenic microorganisms and methods of making and using the same
EP1992351B1 (en) 2007-05-18 2016-05-11 Nestec S.A. Lactobacillus johnsonii for prevention of postsurgical infection
US20090010892A1 (en) 2007-07-06 2009-01-08 Toa Pharmaceutical Co., Ltd. Hyperlipidemia Treatment Agent
US20090010891A1 (en) 2007-07-06 2009-01-08 Toa Pharmaceutical Co., Ltd. Sepsis Treatment Agent
US7919250B2 (en) 2007-07-31 2011-04-05 New York University Diagnostic and treatment methods for characterizing bacterial microbiota in skin conditions
EP2030623A1 (en) 2007-08-17 2009-03-04 Nestec S.A. Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria
US20100284979A1 (en) 2007-10-01 2010-11-11 University College Cork, National University Of Ireland, Cork Modulation of Tissue Fatty Acid Composition of a Host by Human Gut Bacteria
US8478544B2 (en) 2007-11-21 2013-07-02 Cosmosid Inc. Direct identification and measurement of relative populations of microorganisms with direct DNA sequencing and probabilistic methods
US20090143713A1 (en) 2007-11-30 2009-06-04 Jacques Van Dam Biliary Shunts, Delivery Systems, Methods of Using the Same and Kits Therefor
EP2072052A1 (en) 2007-12-17 2009-06-24 Nestec S.A. Prevention of opportunistic infections in immune-compromised subjects
ES2343499B1 (es) 2007-12-24 2011-06-10 Consejo Superior De Investigaciones Cientificas Microorganismos para mejorar el estado de salud de individuos con desordenes relacionados con la ingesta de gluten.
EP2110028A1 (en) 2008-04-15 2009-10-21 Nestec S.A. Bifidobacterium longum and hippocampal BDNF expression
EP2318513B1 (en) 2008-07-11 2012-09-19 Chr. Hansen A/S New probiotic bifidobacterium longum
US8569466B2 (en) 2008-09-10 2013-10-29 Nnochiri Ekwuribe Aromatic carboxylic acid derivatives for treatment and prophylaxis of gastrointestinal diseases including colon cancers
US9603876B2 (en) 2008-09-25 2017-03-28 New York University Compositions and methods for restoring gastrointestinal microbiota following antibiotic treatment
WO2010040055A2 (en) * 2008-10-03 2010-04-08 Intekrin Therapeutics, Inc. Oral pharmaceutical formulations for antidiabetic compounds
MX349705B (es) 2008-11-11 2017-08-09 Alimentary Health Ltd Bifidobacterium longum.
US8785160B2 (en) 2009-02-24 2014-07-22 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
MX2011011659A (es) 2009-05-07 2012-02-28 Tate & Lyle Ingredients France SAS Composiciones y metodos para elaborar alfa-(1,6) oligodextranos ramificados en alfa-(1,2).
MX338680B (es) 2009-05-11 2016-04-27 Nestec Sa Bifidobacterium longum ncc2705 (cncm i-2618) y padecimientos inmunes.
DK3181134T3 (da) 2009-06-19 2020-01-20 Dupont Nutrition Biosci Aps Bifidobakterier til behandling af diabetes og relaterede tilstande
US20150320808A1 (en) 2009-06-19 2015-11-12 Dupont Nutrition Biosciences Aps Bifidobacteria for treating cardiac conditions
US9848760B2 (en) 2009-06-29 2017-12-26 Gearbox, Llc Devices for continual monitoring and introduction of gastrointestinal microbes
BR112012001812B1 (pt) 2009-07-30 2019-04-16 Dupont Nutrition Biosciences Aps Uso de bactéria para o tratamento da endotoxemiametabólica em mamífero
TR201807143T4 (tr) 2009-08-25 2018-06-21 Nestec Sa Bifidobacterium longum ve fonksiyonel gastrointestinal bozukluklar.
CA2776420A1 (en) 2009-10-05 2011-04-14 Aak Patent B.V. Methods for diagnosing irritable bowel syndrome
US20110081320A1 (en) 2009-10-06 2011-04-07 Nubiome, Inc. Treatment/Cure of Autoimmune Disease
CN104206946A (zh) 2009-11-12 2014-12-17 雀巢产品技术援助有限公司 用于促进肠微生物群平衡和健康的营养组合物
ES2648055T3 (es) 2009-12-16 2017-12-28 Probiotical S.P.A. Cepas de bacterias probióticas que producen ácido linoleico conjugado y uso de las mismas para la preparación de una composición farmacéutica
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
NL2004201C2 (en) 2010-02-05 2011-08-08 Friesland Brands Bv Use of sialyl oligosaccharides to modulate the immune system.
EP2556835B1 (en) 2010-02-10 2015-08-05 Japan Eco-Science Co. Ltd. Mixture, dissolving solution and pharmaceutical agent each comprising thermophilic microorganism
IT1398553B1 (it) 2010-03-08 2013-03-01 Probiotical Spa Composizione comprendente batteri probiotici per il trattamento di patologie associate con le alterazioni del sistema immunitario.
FI20105478A0 (fi) 2010-04-30 2010-04-30 Valtion Teknillinen Menetelmä tyypin 1 diabeteksen diagnosoimiseksi ja menetelmiä ja koostumuksia tyypin 1 diabeteksen puhkeamisen estämiseksi
US8951512B2 (en) * 2010-05-04 2015-02-10 New York University Methods for treating bone disorders by characterizing and restoring mammalian bacterial microbiota
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
US9439933B2 (en) 2010-06-28 2016-09-13 Kabushiki Kaisha Yakult Honsha Skin properties improving agent for oral administration
PH12012502532A1 (en) 2010-06-30 2017-08-09 Nestec Sa Use of chicoric acid and lactic bacterium in food supplement for regulating skin pigmentation
US9386793B2 (en) 2010-08-20 2016-07-12 New York University Compositions and methods for treating obesity and related disorders by characterizing and restoring mammalian bacterial microbiota
AU2011299285B2 (en) 2010-09-10 2017-01-05 Ntcd, Llc Environmental Clostridial bacteriotherapy and related formulations and methods of manufacture and use
DK2439264T3 (en) 2010-10-11 2015-08-03 Jennewein Biotechnologie Gmbh Novel fucosyltransferases and their use
US20120165792A1 (en) 2010-12-22 2012-06-28 Ethicon Endo-Surgery, Inc. Pill Catchers
US10245288B2 (en) 2011-02-04 2019-04-02 Joseph E. Kovarik Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease
WO2012118535A1 (en) 2011-03-01 2012-09-07 Quorum Innovations, Llc Materials and methods for treating conditions associated with pathogenic biofilm
EP2683390B1 (en) 2011-03-09 2017-05-03 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
WO2012142605A1 (en) 2011-04-15 2012-10-18 Samaritan Health Services Rapid recolonization deployment agent
ITMI20110793A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri probiotici e composizione sinbiotica contenente gli stessi destinata alla alimentazione dei neonati.
US9463169B2 (en) 2011-08-17 2016-10-11 Microbiome Therapeutics, Llc Human gastrointestinal microbiome modulating food supplement for improving blood glucose regulation
EP2744888B1 (en) 2011-08-18 2017-12-13 Chr. Hansen A/S Method for purifying bacterial cells
EP2753187B2 (en) 2011-08-30 2025-08-06 Caelus Pharmaceuticals B.V. Method for preventing and/or treating insulin resistance
ES2662793T3 (es) 2011-09-14 2018-04-09 Nubiyota Llc Complementos de medio y métodos para cultivar microorganismos anaerobios gastrointestinales humanos
US20130121968A1 (en) 2011-10-03 2013-05-16 Atossa Genetics, Inc. Methods of combining metagenome and the metatranscriptome in multiplex profiles
FI20116008A0 (fi) 2011-10-12 2011-10-12 Maeyrae Maekinen Annika Viskeraalisen rasvan estäminen ja diagnostisointi
US9649346B2 (en) 2011-11-02 2017-05-16 Bios Llc Probiotic stick formulation for skin maintenance and methods of use
ES2993669T3 (en) 2011-12-01 2025-01-03 Univ Tokyo Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
SG11201402993XA (en) 2011-12-07 2014-09-26 Calpis Co Ltd Lipid metabolism and/or sugar metabolism improver containing lactic acid bacterium or treatment product thereof
CN110201003A (zh) 2012-02-29 2019-09-06 伊西康内外科公司 微生物区系的组合物及与其相关的方法
ES2436251B1 (es) 2012-05-25 2014-10-08 Consejo Superior De Investigaciones Científicas (Csic) Bacteroides cect 7771 y su uso en la prevención y tratamiento de sobrepeso, obesidad y alteraciones metabólicas e inmunológicas.
US20130344042A1 (en) 2012-06-20 2013-12-26 Gretchen Tanbonliong Dietary management of celiac disease and food allergy
WO2014011233A1 (en) 2012-07-09 2014-01-16 Trachtman Ira Milton Compositions and method for treatment and prophylaxis of inflammatory bowel disease
WO2014029758A1 (en) 2012-08-20 2014-02-27 Chr. Hansen A/S Method for optimizing a process for freeze drying a bacteria-containing concentrate
KR20210013352A (ko) 2012-09-20 2021-02-03 프로테라 인코포레이티드 비만 및 비만 관련 질환을 치료하기 위한 프로바이오틱 조성물 및 방법
WO2014070014A1 (en) 2012-11-01 2014-05-08 Rijksuniversiteit Groningen Methods and compositions for stimulating beneficial bacteria in the gastrointestinal tract
EP3967315B1 (en) 2012-11-19 2025-05-14 Université catholique de Louvain Akkermansia muciniphila for treating cancer
WO2014075745A1 (en) 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
PL3628161T3 (pl) 2012-11-23 2023-08-07 Seres Therapeutics, Inc. Synergistyczne kompozycje bakteryjne i sposoby ich wytwarzania oraz stosowanie
HK1219022A1 (zh) 2013-02-04 2017-03-24 Seres Therapeutics, Inc. 填充胃肠道的方法
EP3904502A3 (en) 2013-02-04 2022-02-23 Seres Therapeutics, Inc. Compositions and methods
HK1220495A1 (zh) 2013-03-14 2017-05-05 Seres Therapeutics, Inc. 从材料和组合物中检测和富集病原体的方法
US11814664B2 (en) 2013-05-24 2023-11-14 Genomatica, Inc. Microorganisms and methods for producing (3R)-hydroxybutyl (3R)-hydroxybutyrate
CN105106245A (zh) 2015-08-24 2015-12-02 上海交通大学医学院附属瑞金医院 Akkermansia muciniphila BAA-835菌株的应用
CN105030841A (zh) * 2015-08-24 2015-11-11 上海交通大学医学院附属瑞金医院 Akkermansia muciniphila BAA-835菌株的应用

Also Published As

Publication number Publication date
US20190046590A1 (en) 2019-02-14
US20200121736A1 (en) 2020-04-23
US20200246395A1 (en) 2020-08-06
US20130224155A1 (en) 2013-08-29
US11590176B2 (en) 2023-02-28
US10149870B2 (en) 2018-12-11
US9173910B2 (en) 2015-11-03
US10149867B2 (en) 2018-12-11
US12048721B2 (en) 2024-07-30
US20200121734A1 (en) 2020-04-23
WO2013130773A8 (en) 2014-10-16
US20200121733A1 (en) 2020-04-23
CN108771687A (zh) 2018-11-09
WO2013130773A3 (en) 2014-12-18
WO2013130773A2 (en) 2013-09-06
EP2836224A4 (en) 2015-12-16
EP2836224A2 (en) 2015-02-18
US20200237835A1 (en) 2020-07-30
US10729732B2 (en) 2020-08-04
IN2014DN07752A (enExample) 2015-05-15
US20200121735A1 (en) 2020-04-23
CN110201003A (zh) 2019-09-06
US20160113971A1 (en) 2016-04-28
US20200121732A1 (en) 2020-04-23
CN104780932A (zh) 2015-07-15
US20170368108A1 (en) 2017-12-28

Similar Documents

Publication Publication Date Title
BR112014021388A2 (pt) composições de microbiota e métodos rela-cionados às mesmas
BR112015021970A2 (pt) composições à base de nanopartículas
BR112014016810A2 (pt) composições e métodos para tratamento de distúrbios metabólicos
BR112014032699A2 (pt) métodos de tratamento de síndrome metabólica pediátrica
HK1218560A1 (zh) 组成与方法
BR112014030835A2 (pt) composição farmacêutica contendo ácido nicotínico e/ou nicotinamida e/ou triptofano para influenciar positivamente a microbiota intestinal
BR112015000150A2 (pt) composições farmacêuticas dissuasoras de abuso de liberação controlada
BR112013010021A2 (pt) combinações farmacêuticas para o tratamento de distúrbios metabólicos.
BR112012022755A2 (pt) composição com bactérias probióticas para uso no tratamento de distúrbios imunológicos
BR112012024349A2 (pt) métodos de tratamento de carcinoma hepatocelular
BR112015000136A2 (pt) fibra alimentar para uso no tratamento de um efeito colateral gastrintestinal de uma nutrição ou medicamento
BR112012030699A2 (pt) métodos para tratar câncer de bexiga
EA201491358A1 (ru) Вводимые перорально кортикостероидные композиции
EA201401028A1 (ru) Фармацевтическая композиция, содержащая эмпаглифлозин и лекарственное средство от ожирения
BR112015011430A2 (pt) composição para liberação imediata e prolongada
BR112015007814A2 (pt) diagnóstico, prevenção e tratamento de doenças da articulação
BR112015017251A2 (pt) composições farmacêuticas compreendendo doadores de nitroxil
BR112012020989A2 (pt) composições veterinárias
BR112014019399A2 (pt) métodos de tratamento da fibrose
BR112013026661A2 (pt) método de entrega de vacina
BR112014020113A8 (pt) Composições farmacêuticas e método para diminuir a frequência de micção
BR112014021068A2 (pt) Inibidor de uma interação entre fosfatidilserina e um receptor tim, composição farmacêutica e uso de um inibidor
BR112015005942A2 (pt) extratos de cynara scolymus, coffea spp. e olea europaea para tratamento de síndrome metabólica
BR112016023450A2 (pt) uso de compostos ctla4 para alcançar remissão livre de fármacos em indivíduos com artrite reumatoide precoce
BR112013028820A2 (pt) alimento medicinal para declínio cognitivo

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B25A Requested transfer of rights approved

Owner name: THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL (US) ; JOHNSON AND JOHNSON CONSUMER INC. (US)

B25A Requested transfer of rights approved

Owner name: THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL (US) ; JOHNSON AND JOHNSON CONSUMER INC. (US)

B25D Requested change of name of applicant approved

Owner name: THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL (US) ; JOHNSON AND JOHNSON CONSUMER INC. (US)